Deep Track holds 6.78% of Enanta shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Deep Track Capital and affiliates report a 6.78% stake in Enanta Pharmaceuticals Inc. The group, including Deep Track Biotechnology Master Fund and David Kroin, beneficially owns 1,956,867 shares of Enanta common stock, with shared voting and dispositive power over all reported shares.
The ownership percentage is based on 28,862,601 Enanta common shares outstanding as of November 4, 2025, as referenced from the company’s Form 10-K. The reporting persons certify the shares are not held for the purpose of changing or influencing control of Enanta.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Enanta Pharmaceuticals (ENTA) does Deep Track Capital own?
Who are the reporting persons in the Enanta (ENTA) Schedule 13G/A filing?
Is Deep Track’s Enanta (ENTA) stake intended to influence control of the company?
How was Deep Track’s ownership percentage in Enanta (ENTA) calculated?
AI-generated analysis. How Rhea-AI works. Not financial advice.